Presidential Session

[PS-4] Osimertinib after definitive CRT in unresectable stage III EGFRm NSCLC：LAURA Japan cohort analysis

^○Terufumi Kato¹, Toshiaki Takahashi², Koichi Goto³, Takayuki Takahama⁴, Satoshi Oizumi⁵, Shunichi Sugawara⁶, Ellie Grainger⁷, Azura Evans⁷, Toshiaki Ozaki⁸, Tetsu Matsubara⁹, Kota Suzuki⁹, Takako Inoue¹⁰ (1.Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan, 2.Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan, 3.Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan, 4.Department of Medical Oncology, Kindai University Hospital, Osaka, Japan, 5.Department of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan, 6.Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan, 7.Late-stage Development, Oncology R＆D, AstraZeneca, Cambridge, UK, 8.Biometrics, Data Science ＆ Innovation, R＆D, AstraZeneca, Osaka, Japan, 9.Late Development Oncology TA Division, R＆D, AstraZeneca, Tokyo, Japan, 10.Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan)